Clinical efficacy of vinorelbine and cisplatin combined with recombinant human endostatin in treatment of elderly patients with non-small cell lung cancer

Abstract

Objective To analyze the effect of vinorelbine, cisplatin combined with recombinant human endostatin on elderly patients with non-small cell carcinoma. Methods From January 2014 to February 2016, 48 patients with non-small cell lung cancer were selected, according to different treatment modalities, they were divided into observation group and the control group. The control group was given vinorelbine plus cisplatin in routine chemotherapy treatment, the patients in the observation group were given recombinant human endostatin treatment in addition. The curative effect, serum markers and adverse reactions were observed and compared. Results The short-term efficacy, quality of life and physical condition, the degree of improvement of the observation group were significantly better than those of the control group, the differences were significant (P 0.05). Conclusions Cisplatin and vinorelbine combined with recombinant human endostatin in the treatment of elderly patients with non-small cell lung cancer, can effectively enhance the inhibiting effect on tumor growth and improvement of clinical symptoms, prolong the survival time. Key words: Elderly; Non-small cell lung cancer; Recombinant human endostatin; Cisplatin; Vinorelbine